Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum‐resistant ovarian cancer and primary peritoneal carcinomatosis
Daniela Matei(Northwestern University), Gregory P. Sutton(St Vincent Hospital)
Cited by 75
Related Papers
EZH2 inhibition promotes epithelial-to-mesenchymal transition in ovarian cancer cells
|Oncotarget|2016|90
Ovarian Cancer—Why Lipids Matter
|Cancers|2019|80
A Novel ALDH1A1 Inhibitor Targets Cells with Stem Cell Characteristics in Ovarian Cancer
|Cancers|2019|71
Tissue Transglutaminase Regulates Matrix Metalloproteinase-2 in Ovarian Cancer by Modulating cAMP-response Element-binding Protein Activity
|Journal of Biological Chemistry|2009|63
Interferon-γ signaling is associated with BRCA1 loss-of-function mutations in high grade serous ovarian cancer
|npj Precision Oncology|2019|30